Comparative Value of Post-Remission Treatment in Cytogenetically Normal AML Subclassified by NPM1 and FLT3-ITD Allelic Ratio

Post-remission treatment (PRT) in patients with cytogenetically normal (CN)-AML in first complete remission (CR1) is debated. Molecular diagnostic analyses, including NPM1 and FLT3-ITD, provide additional prognostic information that may be used for a risk adapted approach.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Jurjen Versluis, Florentien in 't Hout, Raynier Devillier, Wim van Putten, Markus Manz, Marie-Christiane Vekemans, Marie-Cecile Legdeur, Jakob Passweg, Johan Maertens, Jurgen Kuball, Bart Biemond, Peter Valk, Bert van der Reijden, Giovanna Meloni, Harry S Source Type: research